Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526965 | 0.83 | LOX (0.31) | — | |
| SCHEMBL19677742 | 0.81 | HDAC1 (0.31) | — | |
| SCHEMBL19781318 | 0.79 | — | — | |
| SCHEMBL20929147 | 0.79 | LOX (0.32) | — | |
| SCHEMBL19748358 | 0.79 | KDM1A (0.33) | KDM1AKDM1B | |
| SCHEMBL31529670 | 0.77 | LOX (0.33) | — | |
| SCHEMBL1478000 | 0.77 | LOX (0.35) | — | |
| SCHEMBL14658440 | 0.76 | ACACB (0.39) | — | |
| SCHEMBL19781239 | 0.76 | GABRA1 (0.31) | — | |
| SCHEMBL19781320 | 0.76 | TRPV4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-01-12 | — | — | US | disclosed |
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-10-17 | — | — | US | disclosed |
| CN-109563119-A | α-D- galactoside the inhibitor of galactose agglutinin | 格莱克特生物技术公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018011094-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS3, LGALS2 | KDM1A 3404/4885KDM1B 4542/4885 |
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS3, LGALS2 | KDM1A 3404/4885KDM1B 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.